Jazz Pharmaceuticals (JAZZ) PT Bumped to $175 at Cantor Fitzgerald Amid Positive Xyrem FDA Dispute Resolution
Tweet Send to a Friend
Cantor Fitzgerald analyst Irina Rivkind Koffler bumped her price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $175.00 (from $170.00) but ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
